TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 24091269

Group type: EXPERIMENTAL
Intervention: Early removal group (drainage < 300 ml/24 h), n = 41
Number of subjects: 70

Group type: COMPARATOR
Intervention: Traditional management group (drainage < 100 ml/24 h), n = 29
Number of subjects: 70
Study: 22044691

Group type: EXPERIMENTAL
Intervention: Docetaxel addition to adjuvant anthracycline-based chemotherapy
Number of subjects: 1099

Group type: EXPERIMENTAL
Intervention: Docetaxel addition
Number of subjects: 1099
Study: 19220626

Group type: EXPERIMENTAL
Intervention: Family intervention
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Harsh parenting, responsive parenting, and stimulating parenting improvements
Number of subjects: 0
Study: 19070056

Group type: EXPERIMENTAL
Intervention: Iron supplementation (20 mg day(‐1))
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Zinc supplementation (20 mg day(‐1))
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Iron + Zinc supplementation (20 mg of each day(‐1))
Number of subjects: 79

Group type: COMPARATOR
Intervention: Control (no supplementation)
Number of subjects: 79
Study: 15219777

Group type: EXPERIMENTAL
Intervention: lamotrigine (300 mg)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: 4030W92 (100 mg)
Number of subjects: 15

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: lamotrigine or 4030W92
Number of subjects: 15
Study: 11581138

Group type: EXPERIMENTAL
Intervention: Ramipril
Number of subjects: 827

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 827
Study: 9626282

Group type: EXPERIMENTAL
Intervention: Body weight support (BWS) system with overhead harness, supporting up to 40% of body weight
Number of subjects: 100

Group type: COMPARATOR
Intervention: No body weight support (no-BWS), bearing full weight on lower extremities
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Body weight support (BWS) system with overhead harness
Number of subjects: 100

Group type: COMPARATOR
Intervention: No body weight support (no-BWS)
Number of subjects: 100
Study: 7942679

Group type: EXPERIMENTAL
Intervention: ursodeoxycholic acid
Number of subjects: 178

Group type: EXPERIMENTAL
Intervention: upper endoscopy
Number of subjects: 178

Group type: COMPARATOR
Intervention: none
Number of subjects: 178
Study: 3232497

Group type: EXPERIMENTAL
Intervention: Alizapride 50 mg intravenously
Number of subjects: 170

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 170
Study: 29193743

Group type: EXPERIMENTAL
Intervention: Specialized Early Intervention (SEI) treatment (OPUS treatment)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Fidelity scale for SEI teams
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Fidelity scale components
Number of subjects: 0
Study: 28648698

Group type: EXPERIMENTAL
Intervention: Dabrafenib plus trametinib (D + T)
Number of subjects: 563
Study: 26303617

Group type: EXPERIMENTAL
Intervention: Home Affluence Scale for Children (HASC) <2.0
Number of subjects: 422
Study: 24373262

Group type: EXPERIMENTAL
Intervention: Health Behavioral Modification based on the Client Center Program (HBMCCP) for 8 weeks
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Health Behavioral Modification based on the Client Center Program (HBMCCP)
Number of subjects: 59

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 59
Study: 22018484

Group type: EXPERIMENTAL
Intervention: Low-tilt biphasic waveform (LTBW)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Low-tilt monophasic waveform (LTMW)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Crossover patients (after initial waveform failure)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Overall mean voltage, current, and energy used for cardioversion
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Successful cardioversion patients
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Adverse complications
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Cardiac markers measured postcardioversion
Number of subjects: 30
Study: 19791470

Group type: EXPERIMENTAL
Intervention: Statins
Number of subjects: 78

Group type: COMPARATOR
Intervention: Non-statin
Number of subjects: 78
Study: 16828596

Group type: EXPERIMENTAL
Intervention: RV apical pacing
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Baseline variables (age, gender, history of heart failure, QRS duration in spontaneous rhythm and during pacing, LV end-diastolic and end-systolic diameters, LV ejection fraction, and intra-LV EMD in spontaneous rhythm)
Number of subjects: 56
Study: 12547469

Group type: EXPERIMENTAL
Intervention: Selegiline hydrochloride (5 mg p.o. twice daily)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 10362076

Group type: EXPERIMENTAL
Intervention: HME
Number of subjects: 64

Group type: COMPARATOR
Intervention: CH
Number of subjects: 64
Study: 7488417

Group type: EXPERIMENTAL
Intervention: Granisetron plus hydroxyzine hydrochloride (group G/H)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Granisetron alone (group G)
Number of subjects: 0
Study: 1663466

Group type: EXPERIMENTAL
Intervention: Azithromycin (total dose 1.5 g, given orally in five or six doses over 5 days)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Erythromycin (500 mg orally four times daily for 7 days)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Cloxacillin (500 mg orally four times daily for 7 days)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Azithromycin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Erythromycin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Cloxacillin
Number of subjects: 0
Study: 7103522

Group type: EXPERIMENTAL
Intervention: Dinitrochlorobenzene (DNCB) treatment applied locally in two forms: an acetone solution applied weekly or a cream used every day, with varying concentrations to induce contact dermatitis.
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: DNCB treatment with cimetidine administration to abolish acquired tolerance.
Number of subjects: 42
Study: 30427250

Group type: EXPERIMENTAL
Intervention: Tocilizumab (TCZ)
Number of subjects: 0
Study: 29108741

Group type: EXPERIMENTAL
Intervention: Flavour-Texture (taste, smell, and texture)
Number of subjects: 194

Group type: EXPERIMENTAL
Intervention: Flavour (taste and smell)
Number of subjects: 194

Group type: EXPERIMENTAL
Intervention: Taste only
Number of subjects: 194

Group type: EXPERIMENTAL
Intervention: Smell only
Number of subjects: 194

Group type: EXPERIMENTAL
Intervention: Texture cues in addition to flavour cues for carrot, cucumber, onion, and tomato
Number of subjects: 194

Group type: EXPERIMENTAL
Intervention: Increased perceived intensity of smell, taste, or flavour cues
Number of subjects: 194
Study: 27160841

Group type: EXPERIMENTAL
Intervention: ICU Nurse-Physician Questionnaire (ICU N-P-Q) administered to physicians and nurses
Number of subjects: 2006

Group type: EXPERIMENTAL
Intervention: ICU N-P-Q
Number of subjects: 2006
Study: 25115761

Group type: EXPERIMENTAL
Intervention: Low-molecular-weight heparin (LMWH; reviparin)
Number of subjects: 365

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 365
Study: 22978047

Group type: COMPARATOR
Intervention: Kramer's index
Number of subjects: 50
Study: 20939236

Group type: EXPERIMENTAL
Intervention: Visual inspection with acetic acid
Number of subjects: 1521

Group type: COMPARATOR
Intervention: Cervical cytology
Number of subjects: 1521
Study: 18556849

Group type: EXPERIMENTAL
Intervention: TINTARA uterine manipulator
Number of subjects: 60

Group type: COMPARATOR
Intervention: Cohen cannula
Number of subjects: 60
Study: 16046894

Group type: EXPERIMENTAL
Intervention: Dance and movement program (The Lebed Method, Focus on Healing Through Movement and Dance) for 12 weeks
Number of subjects: 35

Group type: COMPARATOR
Intervention: Wait list control group
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Dance and movement program (The Lebed Method, Focus on Healing Through Movement and Dance)
Number of subjects: 35
Study: 12464949

Group type: EXPERIMENTAL
Intervention: Montelukast (10 mg daily)
Number of subjects: 782

Group type: EXPERIMENTAL
Intervention: Beclomethasone (200 microg twice daily)
Number of subjects: 782

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 782
Study: 10726437

Group type: EXPERIMENTAL
Intervention: Running (R)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Swimming (S)
Number of subjects: 8
Study: 8749592

Group type: EXPERIMENTAL
Intervention: 3-D corrugated surface detection
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Motion coherence task
Number of subjects: 2
Study: 1782137

Group type: EXPERIMENTAL
Intervention: IRT assay for CF screening
Number of subjects: 0
Study: 7299001

Group type: EXPERIMENTAL
Intervention: Peanut oil (1, 2, and 5 ml doses)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Olive oil (control)
Number of subjects: 10
Study: 31675540

Group type: EXPERIMENTAL
Intervention: Smartphone training program (once a week for 20 weeks)
Number of subjects: 344

Group type: COMPARATOR
Intervention: Wait-list control group (no training during the study period)
Number of subjects: 344
Study: 30448776

Group type: EXPERIMENTAL
Intervention: Antibiotics for 5 days and iron-MNPs for 40 days (Fe+Ab+)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Antibiotics and no-iron-MNPs (Fe-Ab+)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: No antibiotics and iron-MNPs (Fe+Ab-)
Number of subjects: 28

Group type: COMPARATOR
Intervention: No antibiotics and no-iron-MNPs (Fe-Ab-)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Fe+Ab+
Number of subjects: 28
Study: 28668686

Group type: EXPERIMENTAL
Intervention: Immediate ART initiation
Number of subjects: 4629
Study: 27589688

Group type: EXPERIMENTAL
Intervention: GP2+GM‐CSF
Number of subjects: 180

Group type: COMPARATOR
Intervention: GM‐CSF alone
Number of subjects: 180
Study: 25000595

Group type: EXPERIMENTAL
Intervention: SUPRA
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: SRP
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: S30SRP
Number of subjects: 25
Study: 21720723

Group type: EXPERIMENTAL
Intervention: Attention-switching tasks (visual and auditory)
Number of subjects: 18
Study: 20969925

Group type: EXPERIMENTAL
Intervention: 1.0 μg VAX125 vaccine
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: 2.0 μg VAX125 vaccine
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: 0.5 μg VAX125 vaccine
Number of subjects: 128

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 128
Study: 17990465

Group type: EXPERIMENTAL
Intervention: Chemotherapy of DCF regimen combined with Chinese herbal medicine
Number of subjects: 66

Group type: COMPARATOR
Intervention: Chemotherapy of DCF regimen alone
Number of subjects: 66
Study: 15792884

Group type: EXPERIMENTAL
Intervention: 1 Hz repetitive transcranial magnetic stimulation (rTMS) over left pre-motor cortex
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: 1 Hz repetitive transcranial magnetic stimulation (rTMS) over left pre-motor cortex followed by right pre-motor cortex
Number of subjects: 5

Group type: COMPARATOR
Intervention: Placebo (not explicitly mentioned in the abstract)
Number of subjects: 5
Study: 12144714

Group type: EXPERIMENTAL
Intervention: Wholegrain diet
Number of subjects: 11

Group type: COMPARATOR
Intervention: Refined-grain diet
Number of subjects: 11
Study: 10189457

Group type: EXPERIMENTAL
Intervention: 150 mL of 60% iodinated contrast material injected at 2 mL/sec (group 1)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: 150 mL of 60% iodinated contrast material injected at 3 mL/sec (group 2)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: 100 mL of 60% iodinated contrast material injected at 3 mL/sec (group 3)
Number of subjects: 75
Study: 1446494

Group type: EXPERIMENTAL
Intervention: Ofloxacin, rifampicin, and isoniazid
Number of subjects: 124

Group type: COMPARATOR
Intervention: Ethambutol, rifampicin, and isoniazid
Number of subjects: 124
Study: 3001780

Group type: EXPERIMENTAL
Intervention: 1‐g marihuana cigarette containing 1.83% delta 9‐tetrahydrocannabinol (THC)
Number of subjects: 10

Group type: COMPARATOR
Intervention: 1‐g marihuana placebo cigarette
Number of subjects: 10
Study: 30031600

Group type: EXPERIMENTAL
Intervention: Interactive Web‐based decision aid
Number of subjects: 90

Group type: COMPARATOR
Intervention: Usual care (an informational brochure)
Number of subjects: 90
Study: 29616749

Group type: EXPERIMENTAL
Intervention: Magnetic therapy: 10 mT, 50 Hz
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Magnetic therapy: 5 mT, 50 Hz
Number of subjects: 106

Group type: COMPARATOR
Intervention: Placebo magnetic therapy
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Magnetic stimulation: 49.2 μT, 195 Hz
Number of subjects: 106

Group type: COMPARATOR
Intervention: Placebo magnetic stimulation
Number of subjects: 106
Study: 26860514

Group type: EXPERIMENTAL
Intervention: Mediterranean diet
Number of subjects: 215

Group type: COMPARATOR
Intervention: Low-fat diet
Number of subjects: 215

Group type: EXPERIMENTAL
Intervention: Mediterranean diet adherence (6-9 points)
Number of subjects: 215
Study: 25844704

Group type: EXPERIMENTAL
Intervention: Active TENS (n=10)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo (n=10)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Both groups after TENS disabled
Number of subjects: 20
Study: 23926420

Group type: EXPERIMENTAL
Intervention: Inhaled dihydroergotamine (MAP0004)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Intravenous dihydroergotamine (IV DHE)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 21879942

Group type: EXPERIMENTAL
Intervention: Mass media campaign
Number of subjects: 1472
Study: 19378358

Group type: EXPERIMENTAL
Intervention: Endoscopic release of the A1 pulley
Number of subjects: 0

Group type: COMPARATOR
Intervention: Open approach
Number of subjects: 0
Study: 17158412

Group type: EXPERIMENTAL
Intervention: Garlic powder (2.1 g/d)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Atorvastatin (40 mg/d)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study: 14634736

Group type: EXPERIMENTAL
Intervention: CT-free image-guided surgical navigation system for acetabular cup placement
Number of subjects: 256
Study: 11062277

Group type: EXPERIMENTAL
Intervention: Nonintensive stroke unit care with a care continuum
Number of subjects: 249

Group type: COMPARATOR
Intervention: Conventional care in general medical wards
Number of subjects: 249

Group type: EXPERIMENTAL
Intervention: Patients with mild stroke
Number of subjects: 249

Group type: EXPERIMENTAL
Intervention: Patients with moderate stroke
Number of subjects: 249

Group type: EXPERIMENTAL
Intervention: Patients with severe stroke
Number of subjects: 249
Study: 9146778

Group type: EXPERIMENTAL
Intervention: Omeprazole 20 mg daily
Number of subjects: 406

Group type: EXPERIMENTAL
Intervention: Omeprazole 20 mg for 3 consecutive days each week
Number of subjects: 406

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 406
Study: 7526001

Group type: EXPERIMENTAL
Intervention: Isoechoic cancers
Number of subjects: 417

Group type: COMPARATOR
Intervention: Hypoechoic cancers
Number of subjects: 417
Study: 3110845

Group type: EXPERIMENTAL
Intervention: DGAVP (desglycinamide‐arginine‐vasopressin) administered intranasally, increasing dose from 0.1 mg on day 1 to 10.0 mg on day 5.
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 20
Study: 29643338

Group type: EXPERIMENTAL
Intervention: Higher blood pressure (systolic blood pressure)
Number of subjects: 339224

Group type: EXPERIMENTAL
Intervention: Higher blood pressure (diastolic blood pressure)
Number of subjects: 339224

Group type: EXPERIMENTAL
Intervention: Genetically predicted QRS traits
Number of subjects: 339224
Study: 26766930

Group type: EXPERIMENTAL
Intervention: 200 mg TeaCrine® (LD)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 300 mg TeaCrine® (HD)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo (PLA)
Number of subjects: 60
Study: 24261584

Group type: EXPERIMENTAL
Intervention: 8 weeks of twice weekly group exercise training plus education
Number of subjects: 267

Group type: COMPARATOR
Intervention: Exercise training alone
Number of subjects: 267
Study: 22391106

Group type: EXPERIMENTAL
Intervention: Escitalopram (SRI antidepressant)
Number of subjects: 811

Group type: EXPERIMENTAL
Intervention: Nortriptyline (tricyclic antidepressant)
Number of subjects: 811

Group type: COMPARATOR
Intervention: NSAIDs
Number of subjects: 811
Study: 20731499

Group type: EXPERIMENTAL
Intervention: Participants experiencing anger
Number of subjects: 0

Group type: COMPARATOR
Intervention: Participants with low expectancy of encountering guns
Number of subjects: 0

Group type: COMPARATOR
Intervention: Participants with high expectancy of encountering guns
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Participants in the 5th study
Number of subjects: 0
Study: 18685511

Group type: EXPERIMENTAL
Intervention: Synbiotic formulation A (3 probiotic strains and FOS)
Number of subjects: 721

Group type: EXPERIMENTAL
Intervention: Synbiotic formulation C (5 probiotics and FOS)
Number of subjects: 721

Group type: EXPERIMENTAL
Intervention: Synbiotic formulation D (5 probiotics and GOS)
Number of subjects: 721

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 721
Study: 16966680

Group type: EXPERIMENTAL
Intervention: Competing early education programs or program components; specific interventions not detailed.
Number of subjects: 0
Study: 14525568

Group type: EXPERIMENTAL
Intervention: Topical anti-inflammatory gel (NSAID)
Number of subjects: 386

Group type: EXPERIMENTAL
Intervention: Transdermal glyceryl trinitrate (GTN)
Number of subjects: 386

Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 386
Study: 10655976

Group type: EXPERIMENTAL
Intervention: Spread enriched with free soyabean-oil sterols (0.8 g/d)
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Spread enriched with sheanut-oil sterols (3.3 g/d)
Number of subjects: 76

Group type: COMPARATOR
Intervention: Control spread (not fortified)
Number of subjects: 76
Study: 8876415

Group type: EXPERIMENTAL
Intervention: CCU sounds audiotape throughout the night
Number of subjects: 60

Group type: COMPARATOR
Intervention: Quiet environment (audiotape of CCU sounds withheld)
Number of subjects: 60
Study: 1304727

Group type: COMPARATOR
Intervention: 0.25 mg of oral triazolam
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 0.15 mg of oral clonidine
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 0.25 mg of oral triazolam and 0.75 mg of intrathecal phenylephrine
Number of subjects: 30
Study: 6089652

Group type: EXPERIMENTAL
Intervention: Intranasal human interferon-alpha 2 (HuIFN-alpha 2) 10(7) IU/day
Number of subjects: 304

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 304

Group type: EXPERIMENTAL
Intervention: Intranasal human interferon-alpha 2 (HuIFN-alpha 2)
Number of subjects: 304
Study: 26362259

Group type: EXPERIMENTAL
Intervention: Teacher Help for ADHD treatment group
Number of subjects: 58

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 58
Study: 30576315

Group type: EXPERIMENTAL
Intervention: Anodal transcranial patterned direct current stimulation during gait
Number of subjects: 15

Group type: COMPARATOR
Intervention: Sham stimulation during gait
Number of subjects: 15

Group type: COMPARATOR
Intervention: Anodal transcranial patterned direct current stimulation during rest
Number of subjects: 15
Study: 27374361

Group type: EXPERIMENTAL
Intervention: Laser therapy (AlGaAs infrared laser 808 nm)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Mock laser therapy (device powered off)
Number of subjects: 24
Study: 25140469

Group type: EXPERIMENTAL
Intervention: Left internal thoracic artery (LITA) for LAD and free right internal thoracic artery (RITA) for circumflex in Group-1 (G-1)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Right internal thoracic artery (RITA) pedicled to LAD and left internal thoracic artery (LITA) pedicled to circumflex in Group-2 (G-2)
Number of subjects: 100
Study: 22221980

Group type: EXPERIMENTAL
Intervention: Advance planning intervention (home visits by a facilitator, group information session about My Preferences)
Number of subjects: 240

Group type: COMPARATOR
Intervention: Control group (three monthly workshops promoting healthy behaviors)
Number of subjects: 240
Study: 19558948

Group type: EXPERIMENTAL
Intervention: (11)C-choline PET/CT
Number of subjects: 38

Group type: COMPARATOR
Intervention: (18)F-FDG PET/CT
Number of subjects: 38
Study: 17681825

Group type: EXPERIMENTAL
Intervention: Shunt placement
Number of subjects: 96

Group type: COMPARATOR
Intervention: No shunt placement
Number of subjects: 96
Study: 15854939

Group type: EXPERIMENTAL
Intervention: Heparin-coated extracorporeal circuits
Number of subjects: 30

Group type: COMPARATOR
Intervention: Noncoated extracorporeal circuits
Number of subjects: 30
Study: 11961147

Group type: EXPERIMENTAL
Intervention: Intravascular gamma radiation with iridium‐192
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo (nonradioactive seeds)
Number of subjects: 120
Study: 9591766

Group type: EXPERIMENTAL
Intervention: Patients with severe mitral regurgitation (n=1)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Patients on therapy (n=13)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Patients with mild mitral regurgitation (n=6)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Patients with moderate mitral regurgitation (n=5)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Patients referred for mitral valve replacement (n=8)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Control subjects (n=13)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Correlation with end-systolic diameter
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Correlation with end-diastolic diameter
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Correlation with left ventricular wall thickness
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Correlation with left atrial dimension
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Correlation with percent fractional shortening
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Correlation with left ventricular mass/body surface area
Number of subjects: 35
Study: 7611750

Group type: EXPERIMENTAL
Intervention: Arm A: 250 mg/m2 of l‐leucovorin and 600 mg/m2 of 5‐fluorouracil weekly
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Arm B: 100 mg/m2 of l‐leucovorin and 370 mg/m2 of 5‐fluorouracil for 5 consecutive days
Number of subjects: 28

Group type: COMPARATOR
Intervention: Arm C: 10 mg/m2 of l‐leucovorin and 370 mg/m2 of 5‐fluorouracil for 5 consecutive days
Number of subjects: 28